7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
Deep-dive into cost-effectiveness analyses from the Heart Protection Study (HPS): cost per QALY, payer coverage, generic pricing reality, and value calculations for high-risk patients considering simvastatin.
What happened after the Heart Protection Study ended: long-term follow-up of simvastatin 40 mg, durability of cardiovascular benefit, post-trial safety signals, and legacy effects in high-risk patients.
A deep-dive into the Heart Protection Study's primary and secondary endpoint results, effect sizes, confidence intervals, subgroup analyses, and time-course patterns for simvastatin 40 mg in high-risk patients.
Deep-dive into Heart Protection Study pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline LDL, diabetes status, and vascular history. Which high-risk patients benefited most from simvastatin 40 mg?
A plain-English deep dive into the Heart Protection Study (HPS), the largest statin RCT ever conducted, which proved simvastatin 40 mg cut major vascular events by 24% across a remarkably broad range of high-risk patients.
A clinical deep-dive into the methodological limitations, enrollment biases, generalizability gaps, and conflict-of-interest concerns surrounding the Heart Protection Study of simvastatin 40 mg.
Deep-dive into the Heart Protection Study (HPS) and how simvastatin 40 mg reshaped statin prescribing for high-risk patients, with methodology analysis, real result tables, and clinical translation.